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Background: There is a critical need for predictive/resistance biomarkers for VEGF inhibitors to optimise their use.
Methods: Blood samples were collected during and following treatment and, where appropriate, upon progression from ovarian
cancer patients in ICON7, a randomised phase III trial of carboplatin and paclitaxel with or without bevacizumab. Plasma
concentrations of 15 circulating angio-biomarkers were measured using a validated multiplex ELISA, analysed through a novel
network analysis and their relevance to the PFS then determined.
Results: Samples (n¼ 650) were analysed from 92 patients. Bevacizumab induced correlative relationships between Ang1 and Tie2
plasma concentrations, which reduced after initiation of treatment and remained decreased until progressive disease occurred.
A 50% increase from the nadir in the concentration of circulating Tie2 (or the product of circulating Ang1 and Tie2) predicted
tumour progression. Combining Tie2 with GCIG-defined Ca125 data yielded a significant improvement in the prediction of
progressive disease in patients receiving bevacizumab in comparison with Ca125 alone (74.1% vs 47.3%, Po1 10 9).
Conclusions: Tie2 is a vascular progression marker for bevacizumab-treated ovarian cancer patients. Tie2 in combination with
Ca125 provides superior information to clinicians on progressive disease in patients with VEGFi-treated ovarian cancers.
Ovarian cancer accounts for 22 000 lives annually in the United
States (Jelovac and Armstrong, 2011) and 7000 each year in the UK
(Jayson et al, 2014). For decades, the combination of surgery and
platinum-based cytotoxic chemotherapy has been used to control
advanced ovarian cancer (Vergote et al, 2010), resulting in
response rates of approximately 70% in advanced disease.
As recurrent disease usually occurs within the first 2 years in
the majority of patients who present with advanced disease,
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maintenance or consolidation therapies were tested but were
largely unsuccessful. However, randomised trials of anti-angiogenic
VEGF pathway inhibitors (Burger et al, 2011; Perren et al, 2011;
Aghajanian et al, 2012; Ledermann et al, 2013; Pujade-Lauraine
et al, 2014; Floquet et al, 2015; Pignata et al, 2015) in ovarian
cancer have shown that the addition of such agents to and/or
following conventional cytotoxic therapy resulted in improved
progression-free survival (PFS) and, in the case of ICON7 (Perren
et al, 2011; Oza et al, 2015), overall survival. On the other hand,
VEGF inhibitors can incur moderate toxicity, are expensive and
yield somewhat modest improvements in survival. There remains a
critical need for biomarkers that predict benefit or progression so
that angiogenesis-targeted therapies can be used more effectively.
Ang2 is generated by activated endothelial cells (Gerald et al,
2013) and acts as a potential mechanism of acquired resistance to
VEGF inhibitors (Daly et al, 2013). We reported recently that
ovarian cancer patients with supra-median plasma concentrations
of Ang1 and infra-median concentrations of Tie2 benefited from
bevacizumab (Backen et al, 2014), whereas those with raised
concentrations of both circulating angiogenesis-associated biomar-
kers or infra-median concentrations of Ang1 did not benefit. Here,
we present the first systematic analysis of angio-biomarker
concentrations in the blood of ICON7 patients taken during
treatment up to the point that progressive disease was diagnosed.
First, we carried out a novel network analysis investigating the
correlation of concentrations between angio-biomarkers to discern
key changes in angio-biomarker behaviour during treatment. We
then applied a hierarchical Bayesian modelling strategy to assess
changes in angio-biomarker concentrations to derive a strategy to
determine biomarker-based prediction of progressive disease that
pertains to patients receiving VEGF inhibitors. The strategy led to
a new clinical concept of ‘vascular progression’, from which
evidence of re-activation of the tumour vasculature can be inferred.
METHODS AND STATISTICS
ICON7 translational research. ICON7 recruited 1528 ovarian
cancer patients of whom most (81.5%) had FIGO stage III/IV
disease. In ICON7, patients were randomised to receive carboplatin
and paclitaxel with or without the anti-angiogenic anti-VEGF
antibody bevacizumab, which was administered with and following
the cytotoxic therapy. The primary end point was PFS, which was 2
months better in the experimental arm than the control regimen.
In a pre-planned analysis, the higher risk patients, who mostly had
advanced stage disease, incurred a statistically significant improve-
ment in overall survival of 4.8 months. The response rates for
patients receiving the experimental (bevacizumab-containing) or
conventional regimen were 67% and 48%, respectively (Perren
et al, 2011; Oza et al, 2015).
Samples for translational research were obtained from all
participating Gynaecologic Cancer Intergroup (GCIG) consortia
except for the Arbeitsgemeinschaft Gyna¨kologische Onkologie
(AGO). Research projects, utilising ICON7 translational research
samples, underwent peer review and were approved by the Trial
Management and Steering Committees. The Ethics Committee
approved the generic use of translational research samples for
angiogenesis and ovarian cancer-related research.
Longitudinal sample collection and multiplex ELISAs. Blood
samples were taken according to differing levels of participation in
translational research. Up to 10 samples were taken from each
patient. These included two pre-treatment samples and samples
taken at the end of the infusion of cycle 1, pre-cycle 2, pre-cycle 6,
at the end of cycle 6 infusion, at 6 months, 9 months, 12 months
and at progression (see Supplementary Table 1). Plasma (EDTA)
was prepared at each centre using standard operating procedures
as described previously (Backen et al, 2014). Samples were
separated into aliquots and frozen at  80 oC, before being
shipped to the central sample bank at the University of Leeds,
UK where they were stored anonymously at  80 oC. Multiplex
ELISAs were used to measure the concentrations of circulating
angio-biomarkers including Ang1, Ang2, FGFb, HGF, PDGFbb,
VEGF-A, VEGF-C, VEGF-D VEGFR1, VEGFR2, GCSF, IL8, KGF,
PLGF and Tie2 using the methods as described previously
(Backen et al, 2014). Ca125 concentrations were determined at
each clinical site.
Outcome measures. The primary outcome of interest was PFS,
defined as the interval from the date of randomisation to the date
of disease progression or death, whichever occurred first. Patients
who were alive without disease progression at the end of the study
were censored at the date of their last assessment. Disease
progression was defined clinically or by the RECIST (2010
(http://www.recist.com/index.html); Therasse et al, 2000) criteria.
Asymptomatic progression on the basis of Ca125 concentrations
was insufficient to define progression. The secondary outcome of
the trial was tumour response, which was evaluated at cycle 6 of the
treatment according to RECIST criteria.
Statistical analysis
Network analysis of angio-biomarkers. Angio-biomarkers are
proteins functionally related to the regulation of angiogenesis
(Backen et al, 2014). The correlations between the concentrations
of all angio-biomarkers in response to an angiogenesis-related
treatment were determined. Data collected at progression were not
included to focus on changes of correlation as a result of treatment
effect, while avoiding the biological impact of disease progression
and resistance to treatment. We generated network representations
of these correlations on the basis of: (i) all patients before
treatment, (ii) patients on the standard arm during treatment and
(iii) patients on the experimental arm during treatment. Both
Pearson’s correlation and partial correlation were used to construct
the networks, which were plotted using the ‘qgraph’ package
(Epskamp et al, 2012) of R 3.1 (R Development Core Team, 2014).
Illustrating dynamics of angio-biomarkers. The dynamics of each
angio-biomarker, measured as log ratios over the baseline, were
plotted against the percentage time that elapsed between
randomisation and the date of progression/censoring (%PFS; time
divided by each patient’s PFS interval). Missing data were
interpolated for illustration purposes only. At each 10% interval
of PFS time, angio-biomarker concentrations in the two arms were
compared using Mann–Whitney U tests.
Correlating angio-biomarker with tumour response. Angio-
biomarker concentrations were investigated for their relationship
with tumour response, evaluated at cycle 6 of treatment, by
comparing angio-biomarkers from patients with complete
response with patients with stable disease using Mann–Whitney
U tests. Patients with partial response were not included to
highlight the potential angio-biomarker contrast. The same
analysis was carried out for Ca125. Patients with Ca125
concentrations less than 30 IU l 1 (tumour undetectable according
to GCIG criteria) prior to treatment were not included in these
analyses.
Bayesian hierarchical modelling of biomarker trajectories. The
trajectories of angio-biomarkers were modelled using a Bayesian
hierarchical modelling approach from actual rather than inter-
polated data. It was hypothesised that there was an inflection point
in the trajectory of a selected angio-biomarker, which from a
clinical point of view was taken to reflect a change in tumour
behaviour and therefore as the earliest sign of tumour progression.
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We approximated the trajectory of an angio-biomarker using a
piecewise-linear time relationship where an inflection point
separates the decreasing part of the trajectory from the subsequent
increasing part. Let t denote time measured from treatment start,
the piecewise-linear angio-biomarker trajectory for a generic
individual was taken to obey:
Cbiomarker tð Þ ¼ aþS tinflection-t
 
btþS t-tinflection
 
btinflectionþg t-tinflection
  þe
ð1Þ
where C represents the concentration of a angio-biomarker, a is the
pre-treatment concentration of the angio-biomarker, tinflection is the
unknown time when inflection occur, b and g are the slopes before
and after the inflection point. e is an Gaussian error term with
unknown variance. S is an indicator function where
S xð Þ ¼ 1 if x40
0 if x  0

:
Prior distributions were assigned to these parameters in accordance
with the structure of a Bayesian hierarchical model. Any unknown
parameters were estimated from the data using a Markov Chain
Monte Carlo approach, as implemented in WinBUGS 1.4 (Imperial
College and MRC, UK). The rationale of applying this model and
details of how the model was implemented can be found in
Supplementary Material 1.
Developing rules for clinical implementation. On the basis of the
Bayesian hierarchical models developed retrospectively using
angio-biomarker trajectories, our next step was to develop criteria
for using the selected angio-biomarkers in clinic, that is, providing
an early prediction of tumour progression while monitoring the
angio-biomarkers during treatment. We evaluated rules similar to
the GCIG criteria for Ca125, where the elevation of a biomarker
with respect to its nadir point is compared with a designated
‘alarm’ threshold.
The Bayesian model allowed ‘pseudo-trial’ data to be generated
via random sampling of the estimated posterior distribution of an
angio-biomarker’s trajectory (Supplementary Material 1). Instead
of creating new pseudo-patients, all the simulated data were
generated based on biomarker trajectories of existing patients, as if
the trial were repeated on the same patients and data were collected
based on new collection scheme. Essentially, this is an inference
process similar to interpolating values of missing data points.
Five thousand simulation data were generated per patient per
angio-biomarker. Concentrations of angio-biomarkers were
imputed on a monthly basis (30±5 days), and were monitored
sequentially as if they were measured in clinic. Tumour progres-
sion was considered if elevation from the nadir point exceeded a
designated cut-off. We sought a threshold value that allowed the
angio-biomarker to predict disease progression for as many
patients as possible at a time reasonably close to the genuine date
of progression, leaving sufficient time for an effective change in
treatment to be planned. The performance of different thresholds
was compared by plotting the percentage of patients that a
biomarker failed to provide any prediction (1–biomarker predic-
tion rate) against time of prediction relative to patient PFS
(prediction quality).
RESULTS
The characteristics of the 92 patients from the ICON7 trial are
shown in Table 1. Forty-four patients were in the standard arm,
where patients received carboplatin and paclitaxel, and 48 were in
the experimental arm, where patients received additional bevaci-
zumab. As expected, the majority of patients had high-grade serous
FIGO stage IIIc disease that had undergone cytoreductive surgery
leaving less than 1 cm residual disease. Demographic character-
istics and histological types for the patients were similar to those of
all patients in ICON7 trial. However, the median age of the
experimental arm was significantly lower (Kruskal–Wallis test,
P¼ 0.03). In total, 350 and 300 useable blood samples were
provided from patients in the experimental arm (7.3±2.5 samples
per patient) and from patients receiving standard cytotoxic therapy
(6.8±2.4 samples per patient).
Ang1-Tie2-VEGF-C regulatory networks induced by bevacizumab.
Correlation network analyses were used to identify changes in the
correlations of angio-biomarker concentrations that were induced
by cytotoxic therapy alone or through the addition of bevacizumab
to the cytotoxic regimen. Before treatment, angio-biomarker
concentrations formed a highly correlated cluster, suggesting some
coordination of biological functions (Figure 1A). Networks from
the standard or the experimental arm alone revealed the same
topology. Partial correlation analysis (Figure 1B) indicated that
Tie2 concentrations correlated with those of VEGF-A, VEGF-C
and HGF. The data also suggested a negative correlation between
Ang1 and Ang2.
Following treatment with carboplatin and paclitaxel, the
pre-treatment angio-biomarker cluster split into two correlated
sub-clusters that were weakly linked by IL-8 (Figure 1C). This is
consistent with increased tumour cell death, which may have
reduced angiogenesis. Partial correlation analysis also demon-
strated that correlations between angio-biomarkers were weakened
in general (Figure 1D).
In the experimental arm, in which bevacizumab was added, the
correlation network remained largely unchanged compared with
that from the standard arm, indicating that patients in the two
arms were subject to similar treatment effect, for example, cancer
cell death. However, the concentration of Ang1 was found to
correlate with Tie2 (Figure 1E), and partial correlation analysis
(Figure 1F) further revealed a highly positively correlated cluster
that included Ang1, Tie2, VEGF-C and PDGF-BB. The positive
correlation between PDGF-BB and Ang1 was present in all
networks, perhaps indicating a coordinated role in the regulation
of vascular maturity, although potentially the central role of
platelets and/or change in platelet concentration cannot be
excluded as the explanation. This unbiased approach led us to
focus attention on the angiopoietin signalling system.
Plotting angio-biomarker trajectories. The concentration–time
trajectories of angio-biomarkers are shown in Figure 2 and
Supplementary Figure 1. Notably, concentrations of Tie2 reduced
in patients treated with bevacizumab, demonstrating a significant
difference between the two arms (P¼ 7.2 10 6 at 30% PFS
time). However, the difference was no longer significant at the
point of disease progression (Figure 2A). Ang1 demonstrated a
similar trajectory but the difference between the two arms was not
significant (Figure 2B).
As current management of ovarian cancer strongly relies on
changes in Ca125 concentrations, we included this ‘gold standard’
factor in our analysis. The trajectory of Ca125 concentration
during treatment is shown in Figure 2C. Ca125 was more
profoundly reduced in the experimental arm (P¼ 0.01), presum-
ably because of the superior efficacy of the combined therapy. No
significant difference was found in any angio-biomarker between
patients with complete tumour response and patients with stable
disease.
Bayesian modelling of biomarker trajectories. We next sought to
develop strategies to identify biomarkers that could be used to
define progression. This focused our attention on Ang1 and Tie2,
which were ligand and receptor, because their concentrations
did not correlate until patients were treated with bevacizumab
(correlation coefficient of 0.09 pre-treatment and 0.43 post-treatment,
BRITISH JOURNAL OF CANCER Tie2 as a vascular progression biomarker
230 www.bjcancer.com |DOI:10.1038/bjc.2016.194
respectively). In addition, further evidence to focus on this pathway
was attributed to Tie2, which demonstrated the most profound
reduction in concentration in bevacizumab-treated patients. These
angio-biomarkers were evaluated by applying a Bayesian Markov
Chain Monte Carlo modelling approach to investigate the
trajectories of (i) Tie2 alone and (ii) Ang1 and Tie2 together,
denoted as Ang1Tie2, where the two proteins were studied as
the product of Tie2 and log2 transformed Ang1 (Supplementary
Material 1). Ca125 was also interrogated using the same approach
to validate the modelling strategy.
We proposed that an inflection point in the gradient of the
concentration–time curve would provide information on the
development of progressive disease. Thus, progression for a
specific angio-biomarker would be observed when an angio-
biomarker concentration that had been decreasing over time,
started to increase in concentration. The results of Bayesian
Table 1. Patients’ characteristics
TRICON7 ICON7–main triala
Standard (N¼44) Bevacizumab (N¼48) Standard (N¼764) Bevacizumab (N¼764)
Age–years
Median (range) 60 (38–75) 53 (31–71)b 57 (18–81) 57 (24–82)
Race–n (5)
White 41 (93) 43 (90) 737 (96) 730 (96)
Asian/Black/Other 3 (7) 5 (10) 27 (4) 34 (4)
ECOG PS–n (%)c
0 16 (37) 23 (48) 358 (47) 334 (45)
1 27 (63) 23 (48) 354 (47) 366 (49)
2 0 2 (4) 43 (8) 45 (6)
Origin of cancer–n (%)
Ovary epithelial 42 (95) 38 (79) 667 (87) 673 (88)
Fallopian tube 1 2 29 (4) 27 (4)
Primary peritoneal 1 8 (17) 56 (7) 50 (6)
Multiple sites 0 0 12 (2) 14 (2)
Histology–n (%)
Serous 32 (73) 40 (83) 529 (69) 525 (69)
Mucinous 1 0 15 (2) 19 (2)
Endometrioid 5 (11) 4 57 (7) 60 (8)
Clear cell 5 (11) 3 60 (8) 67 (9)
Mixed 0 0 48 (6) 40 (5)
Other 1 1 55 (7) 53 (7)
FIGO stage–n (%)
I/IIA 4 (9) 5 (10) 75 (10) 67 (9)
IIB/IIC 5(11) 2 70 (9) 70 (9)
III 0 1 14 (2) 18 (2)
IIIA 3 1 32 (4) 22 (3)
IIIB 2 8 (17) 44 (6) 45 (6)
IIIC 26 (59) 26 (54) 432 (57) 438 (57)
IV 4 (9) 5 (11) 97 (12) 104 (13)
Grade–n (%)
Grade 1 1 2 56 (7) 41 (5)
Grade 2 9 (20) 5 (10) 142 (19) 175 (23)
Grade 3 34 (77) 41 (85) 556 (74) 538 (71)
Unknown 0 0 10 10
Debulking surgery–n (%)
No (inoperable)d 0 0 17 (2) 13 (2)
Yes 44 (100) 48 (100) 747 (98) 751 (98)
41 cm residual disease 16 (36) 15 (31) 195 (26) 192 (26)
p1 cm residual disease 28 (64) 33 (69) 552 (74) 559 (74)
Intent to start chemotherapy following surgery–n (%)
p4 weeks 13 (30) 23 (48) 328 (43) 326 (43)
44 weeks 31 (70) 25 (52) 436 (57) 438 (57)
BMI–kgm2 e
Median (range) 25.3 (18.4–35.2) (23.3 17.9–37.6) Not reported Not reported
Smokinge
Current 2 (5) 4 (8)
Never/ex-smoker 41 (95) 44 (92) Not reported Not reported
Abbreviations: BMI¼body mass index; PS¼performance status.
aData from appendix to (Perren et al, 2011).
bKruskal–Wallis test, P¼ 0.030.
cMissing data on PS in one patient.
dInoperable cases were excluded in TRICON7.
eMissing BMI and smoking data in one patient.
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Figure 1. Analysis of correlation networks. (A) Pearson’s correlation network for all patients pre-treatment. (B) Partial correlation network for all
patients pre-treatment. (C) Pearson’s correlation network for patients on the standard arm, during treatment. (D) Partial correlation network for
patients on the standard arm, during treatment. (E) Pearson’s correlation network for patients on the experimental arm, during treatment. (F) Partial
correlation network for patients on the experimental arm, during treatment. Pearson’s correlation networks were plotted on the left panel (A, C, E)
and partial correlation networks were plotted on the right (B, D, F). Each row of plots, from top to bottom, demonstrated the correlation networks
for patients at baseline, on standard arm during treatment and on experimental arm during treatment, respectively. Each node in the networks
represents one angio-biomarker. The thickness of the edge between two nodes represents the strength of correlation. Positive correlations are red
solid lines and negative correlations, green dashed lines. Correlations with absolute values smaller than 0.3 were not displayed. The thickest line
represents a maximum correlation of 0.74 while the median correlation shown in the networks is 0.55. Angio-biomarkers are highlighted if they
demonstrate significant changes in correlation.
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modelling confirmed this hypothesis of inflection points for Tie2
and for Ang1Tie2 in patients on the experimental arm, but not
in patients on the standard arm (Table 2), which is consistent with
Figure 2. Thus, bevacizumab has a specific effect on Tie2 and on
Ang1Tie2, suggesting that Tie2 or Ang1Tie2 might be a
useful biomarker for vascular activity. On the other hand, Ca125
models were similar for the two different arms, confirming that
Ca125 reflects tumour burden, while suggesting that the angio-
poietin pathway provides information on vascular biology; a
separate compartment.
Rules for biomarker implementation in clinical practice. Having
developed the methodology for inflection point analysis, we set out
to derive rules that were analogous to the GCIG criteria for Ca125
(Rustin et al, 2011), allowing us to define angio-biomarker
progression. Bayesian models underpinned pseudo-trials for each
individual patient in which we developed and tested potential
clinical rules for predicting tumour progression. Testing this
approach on the validated biomarker, Ca125 (Figure 3), we showed
that the optimum behaviour of Ca125 as a biomarker for
progression corresponded exactly with the GCIG criteria that
define progressive disease (red solid line), increasing confidence in
and validating our modelling strategy. The pseudo-trial data
predicted progression through analysis of Ca125 to the same extent
that we observed in the trial itself (48.9% of patients according to
GCIG criteria), also lending credence to our approach.
Our data showed that tumour progression could be predicted in
bevacizumab-treated patients if the concentration of Tie2 (or
Ang1Tie2) increased by 50% from the nadir point during
longitudinal measurements (Figure 3), an event we termed
‘vascular progression’. As a biomarker for progression, Ang1
Tie2 performed only marginally better than Tie2 alone. Therefore,
we focused further investigation on Tie2 alone by combining the
data with those of Ca125.
By searching for an increase in either Ca125 (GCIG criteria) or
Tie2 concentrations (50% increase above nadir) as the criteria for
identifying progression, the performance of the progression
prediction model improved further, such that progression in
74.1% of patients was predicted, a result that was superior to the
performance of either biomarker alone, where less than 50% of
progression episodes were predicted (Mann–Whitney U test,
Po1 10 9). Taken together, our data suggest that simple rules
describing Ca125 and Tie2 can be used to identify progressive
disease in ovarian cancer patients treated with cytotoxic-bevacizu-
mab combination regimens.
DISCUSSION
The minimally invasive nature of blood sampling compared with
serial biopsy makes routine longitudinal monitoring possible for
most cancer patients and such ‘liquid biopsies’ are increasingly
recognised as pivotal to the development of personalised medicine
in oncology. In this study, a correlation network analysis was
applied to discern changes in angio-biomarkers that were specific
to the effect of bevacizumab. In particular, we showed that Ang1
and Tie2 were co-modulated by bevacizumab with reductions in
their plasma concentrations upon the introduction of bevacizumab
followed by a return to pre-treatment concentrations as progressive
disease occurs.
Our goal was to identify biomarkers that would optimise use of
bevacizumab in terms of its efficacy, toxicity and expense. To
address this issue, a hierarchical Bayesian Markov Chain Monte
Carlo modelling approach was applied to quantify trajectories of
angio-biomarker concentrations during treatment. This approach
allowed missing data to be handled and was capable of developing
optimal rules of applying the angio-biomarkers in clinical
implementation. Although successful, greater stability in the data
in future studies would be achieved through more frequent, later
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Figure 2. Mean trajectory of Ang1, Tie2 and Ca125. The dynamics of
Ang1, Tie2 and Ca125, measured as mean percentage change over
baseline (log ratio), were plotted against percentage of PFS. The red
solid line refers to the experimental arm, and the blue dashed line
refers to the standard arm. The data points are presented as ±s.e.
Mann–Whitney U tests were used to compare the two arms at each
10% time interval and the minimum P-value was listed. P-values smaller
than 0.0003 can be considered as indicating significant difference
between the two arms, in accordance with Bonferroni correction for
multiple comparison. As Ca125 (2c) was not subject to multiple
comparisons, it achieved statistical significance with P¼0.01. The first
time point represents the mean of the two pre-treatment samples.
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blood sampling for patients taking part in studies to qualify anti-
angiogenic therapy resistance biomarkers.
The data showed that Tie2 or Ang1Tie2 are useful predictors
of progression in patients receiving bevacizumab but that the small
extra benefit of the more complex product of the two angio-
biomarker concentrations (Ang1Tie2) does not justify its further
evaluation. Instead, we were able to develop a simpler biomarker
rule, analogous to the GCIG criteria for Ca125 (Rustin et al, 2011),
in which a 50% increase in plasma Tie2 concentration from nadir
was, when used with Ca125 progression criteria, superior to
conventional biochemical definitions of disease progression.
This study is based on relatively small cohorts of patients, yet
certain findings reinforce the strength of our data: (i) that the
changes in Tie2 were restricted to patients treated with
bevacizumab and were not seen in those treated with cytotoxic
agents implies that the change in Tie2 concentration relates to the
effect of bevacizumab on tumour vasculature; (ii) this differential
effect was not seen with Ca125, which was modulated in both
arms; (iii) such changes in Tie2 have been identified before albeit
in the context of the VEGF receptor tyrosine kinase inhibitor,
cediranib, when used to treat glioma (Batchelor et al, 2010). The
latter report is important as the uniform behaviour of Tie2 in
different disease settings (ovarian cancer and glioma) and between
different VEGF pathway inhibitors (bevacizumab and cediranib)
imply that this is a class-relevant finding that pertains to tumour
vasculature in general rather than a particular disease type or
specific anti-angiogenic treatment.
Our findings demonstrated that the Tie2 changes are seen in
bevacizumab-treated patients only and they are not associated with
tumour response, suggesting that they are related to tumour
vasculature rather than tumour cell compartment. On the other
hand, concentrations of Ca125 were associated with the volume of
tumour cells. This may explain why a combination of Tie2 and
Ca125 provided a superior prediction of tumour progression
compared with Ca125 alone. This then identifies a new concept in
ovarian cancer, namely that of vascular progression, in which
reactivation of the tumour vasculature occurs once the benefit from
a VEGF inhibitor has been exhausted. Conceptually this could be
important, as we know from recent data that other anti-angiogenic
agents are active in ovarian cancer. Our data have identified in the
pre-treatment and on-treatment blood samples that the Ang/Tie
pathway provides predictive information about the optimum use of
bevacizumab. Therefore, we can now ask whether the concept of
vascular progression during treatment with VEGF inhibitors
identifies the optimum use of Ang/Tie inhibitors in the disease.
We know that the most widely evaluated Ang inhibitor,
trebananib, is active as a single agent (Herbst et al, 2009) in
ovarian cancer, yet in phase III trials in biologically unselected
patients, the drug was modestly active in one phase III trial (Monk
et al, 2014). Careful selection of patients based on the biology of
their disease will be essential if we are to use anti-angiogenic agents
as effectively as possible in ovarian cancer. Thus, the hypothesis to
which our work leads is whether the optimum position of Ang/Tie
inhibitors in ovarian cancer is when there is evidence of vascular
progression based on a rising plasma Tie2 concentration in
patients receiving treatment with a VEGF pathway inhibitor.
Clearly, further experimental research and prospective clinical
trials are now warranted to address this important question and
the potential utility of Tie2 as a vascular progression biomarker for
bevacizumab in ovarian cancer.
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b (slope before inflection point) c (slope after inflection point)
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Ca125 4.4  4.4 0.6 0.9 1.0 0.7
The trajectories of Tie2, Ang1Tie2 and Ca125 were modelled using the Bayesian Markov Chain Monte Carlo modelling approach, and the estimated values for major parameters are
summarised in the table. In the experimental arm, all putative biomarkers demonstrated negative slopes before the inflection point in trajectories, followed by positive slopes after the inflection
point. These results confirmed the validity of the hypothesis on inflection points. In the standard arm, however, significantly different trajectories were observed on Tie2 and Ang1Tie2. Only
the trajectories of Ca125 were consistent in both arms. The bold values indicate significant P-values.
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Figure 3. Tie2 in combination with Ca125 provides better prediction
on tumour progression. The performance of Tie2, Ang1Tie2 and
Ca125 as biomarkers for predicting tumour progression is shown.
1–biomarker prediction rate is plotted against percentage of PFS time
when a prediction is made. Data points close to the top left corner
indicate superior performance. The red solid line represents the
performance of using Ca125 and the GCIG criteria are shown as a red
circle. The green dashed line and the blue dotted line represent the
performance of Tie2 and Ang1Tie2 as resistance biomarkers,
respectively. The highlighted dots on these lines correspond to using
50% elevation from nadir points as criteria for prediction. It
demonstrated that if Tie2 was used in conjunction with Ca125, a better
prediction can be made compared with using either one alone, as
indicated by the black diamond. The combination of Tie2 and Ca125
predicted tumour progression in 74.1% of patients at an average of
62.8%±14.1 %PFS time.
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